Targeting N6-methyladenosine reader YTHDF1 with siRNA boosts antitumor immunity in NASH-HCC by inhibiting EZH2-IL-6 axis-Reference-Cited by-同舟云学术

Targeting N6-methyladenosine reader YTHDF1 with siRNA boosts antitumor immunity in NASH-HCC by inhibiting EZH2-IL-6 axis

Published:2023-11 Issue:5 Volume:79 Page:1185-1200
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Wang Lina,Zhu Lefan,Liang Cong,Huang Xiang,Liu Ziqin,Huo Jihui,Zhang Ying,Zhang Yifan,Chen Lili,Xu Hongzhi,Li Xiaoxing,Xu Lixia,Kuang Ming,Wong Chi Chun,Yu Jun^ORCID

Publisher

Elsevier BV

Subject

Hepatology

Reference29 articles.

1. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention;Huang;Nat Rev Gastroenterol Hepatol,2021

2. NASH: regulatory considerations for clinical drug development and U.S. FDA approval;Harvey;Acta Pharmacol Sin,2022

3. Advances in immunotherapy for hepatocellular carcinoma;Sangro;Nat Rev Gastroenterol Hepatol,2021

4. NASH limits anti-tumour surveillance in immunotherapy-treated HCC;Pfister;Nature,2021

5. The role of m6A modification in the biological functions and diseases;Jiang;Signal Transduct Target Ther,2021

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Different regulatory effects of Lycium barbarum polysaccharide components on gut microbiota in vivo and in vitro;Food Bioscience;2024-10

2. From MASLD to HCC: What's in the middle?;Heliyon;2024-08

3. The YTH domain‐containing protein family: Emerging players in immunomodulation and tumour immunotherapy targets;Clinical and Translational Medicine;2024-08

4. The crosstalk between cellular survival pressures and N6-methyladenosine modification in hepatocellular carcinoma;Hepatobiliary & Pancreatic Diseases International;2024-08

5. New insights into the mechanism of resistance to lenvatinib and strategies for lenvatinib sensitization in hepatocellular carcinoma;Drug Discovery Today;2024-08